Contrave Extended-Release is a Oral Tablet, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Nalpropion Pharmaceuticals Llc. The primary component is Naltrexone Hydrochloride; Bupropion Hydrochloride.
| Product ID | 51267-890_74062009-01b3-4270-9080-139e0f0e29c9 | 
| NDC | 51267-890 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | Contrave Extended-Release | 
| Generic Name | Naltrexone Hydrochloride And Bupropion Hydrochloride | 
| Dosage Form | Tablet, Extended Release | 
| Route of Administration | ORAL | 
| Marketing Start Date | 2014-10-22 | 
| Marketing Category | NDA / NDA | 
| Application Number | NDA200063 | 
| Labeler Name | Nalpropion Pharmaceuticals LLC | 
| Substance Name | NALTREXONE HYDROCHLORIDE; BUPROPION HYDROCHLORIDE | 
| Active Ingredient Strength | 8 mg/1; mg/1 | 
| Pharm Classes | Opioid Antagonist [EPC],Opioid Antagonists [MoA],Aminoketone [EPC],Dopamine Uptake Inhibitors [MoA],Increased Dopamine Activity [PE],Increased Norepinephrine Activity [PE],Norepinephrine Uptake Inhibitors [MoA] | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2021-12-31 | 
| Marketing Start Date | 2014-10-22 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| Marketing Category | NDA | 
| Application Number | NDA200063 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Marketing Start Date | 2014-09-10 | 
| Marketing End Date | 2017-05-17 | 
| Marketing Category | NDA | 
| Application Number | NDA200063 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Billing Unit | EA | 
| Marketing Start Date | 2014-10-22 | 
| Ingredient | Strength | 
|---|---|
| NALTREXONE HYDROCHLORIDE | 8 mg/1 | 
| SPL SET ID: | 485ff360-32c8-11df-928b-0002a5d5c51b | 
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 43063-772 | Contrave | naltrexone hydrochloride and bupropion hydrochloride | 
| 50090-2868 | CONTRAVE | naltrexone hydrochloride and bupropion hydrochloride | 
| 50090-2945 | Contrave | naltrexone hydrochloride and bupropion hydrochloride | 
| 51267-890 | Contrave | naltrexone hydrochloride and bupropion hydrochloride | 
| 64764-890 | CONTRAVE | naltrexone hydrochloride and bupropion hydrochloride | 
| Mark Image Registration | Serial | Company Trademark Application Date | 
|---|---|
|  CONTRAVE  86026234  5181874 Live/Registered | Orexigen Therapeutics, Inc. 2013-08-01 | 
|  CONTRAVE  78979619  3393576 Live/Registered | NALPROPION PHARMACEUTICALS LLC 2006-01-06 | 
|  CONTRAVE  78794374  not registered Dead/Abandoned | AGrow Tech LLC 2006-01-18 | 
|  CONTRAVE  78786858  not registered Dead/Abandoned | Orexigen Therapeutics, Inc. 2006-01-06 | 
|  CONTRAVE  77926232  not registered Dead/Abandoned | Orexigen Therapeutics, Inc. 2010-02-02 | 
|  CONTRAVE  77925784  not registered Dead/Abandoned | Orexigen Therapeutics, Inc. 2010-02-02 | 
|  CONTRAVE  77811077  not registered Dead/Abandoned | Orexigen Therapeutics, Inc. 2009-08-24 |